Phacilitate Early Development Forum 2005 - Opportunities in Beijing

Breakfast Briefing on Oct. 6th 2005

"Opportunities in Beijing—R&D Services"

The Beijing delegation will include some or all of the following individuals. To confirm who will definitely be in attendance please e-mail team@phacilitate.co.uk.

Head of Delegation:
Ms. Yuqin Cui, Assistant Director & Manager of Beijing Pharm. & Biotech.Center

Delegates:

Mr. Junxing Dong, Director of Pharmaceutical Department of Beijing Institute of Radiation Medicine

Mr. Shuchen Liu, Assistant Director of R&D Division of Beijing Institute of Radiation Medicine

Mr. Song Wu, Chairman of Institute of Materia Medica of Chinese Academy of Medical Sciences in R&D

Mr. Yongqing Cheng, CEO & Board Director of Beijing Tri-Prime Genetic Engineering Co., Ltd

Mr. Jianbo Sun, Senior Vice President of Beijing Tri-Prime Genetic Engineering Co., Ltd

Mr. Zhenwen Duan, General Manager of Beijing WBL Peking University Biotech Co., Ltd; Senior Engineer of the Peking University

Mr. Shuren Guo, Chief Technological Officer of Beijing WBL Peking University Biotech Co., Ltd.

Mr. Yiyou Chen, President & Chief Scientific Officer of Starvax Inc.

Ms. Xiaobing Wu, Chief Scientific Officer of Vector Gene Technology Co., Ltd. (VGTC)

Mr. Feng Gao, General Manager, Mediking Pharmaceutical Co. Ltd.

Ms. Zen,Chung Hei Hayley, CEO, Herb King Life Sciences, Inc.

Beijing Pharma & Biotech Center ( BPBC)

Brief Introduction:

BPBC, Beijing Pharma. & Biotech. Center is one of the best Chinese professional consulting agencies, which belongs to Beijing Municipal Commission for Science and Technology (BMCST). Its business model can best be described as a none-profit organization (NPO) with the aim of strengthening the innovative of pharmaceutical and biotechnology industry.

The function of BPBC can be described as the pivot of the industry which is composed of government agencies, research institutions, well-known universities, biomedical enterprises and academic organizations. It is also the bridge across the industry and outside, including overseas industries, foreign scholars, overseas Chinese professors and students, and domestic industries.

Delegate:

Ms. Yuqin Cui, Professor, Director Assistant and Manager of Project Management Division of BPBC

CV:

Professor of Sinkiang Medical University
More than ten years experiences in new drugs’ R&D, especially in TCM.
Abundant experiences in project management. As the manager of Project Management Division of BPBC from 2001 till now, she participated in the designing and organizing of some key research projects of Beijing Government many times.
Familiar with current situations of Beijing’s capabilities of R&D for new drugs.
Tel: 86-01 82802488-817; Fax: 8601 82802515
E-mail: cuiyuqin@newlife.org.cn
Website: www.nwelife.org.cn

Beijing Institute of Radiation Medicine

Brief Introduction:

Beijing Research Institute of Radiation Medicine, which established in early 1950s, is a national comprehensive research institution with advanced facilities, rich human resources, and strong research capabilities. The Institute consists of 11 departments including Experimental Therapy of Radiation Sickness, Pharmacology & Toxicology, Experimental Hematology, Radiation Toxicology &Radiation Hygiene and Protection, Bio-chemistry and Molecular Biology , Radiation Protection and Health physics, Pharmaceutical Chemistry, Experimental Pathology, Immunology and Blood Products, Medical Protection against Laser and Bio-informatics. There are one National Scientific Academician, one National Engineering Academician, about 12 supervisors for doctoral degree, 53 supervisors for master’s degree and more than 300 employees including researchers, technologists, lab assistants and managers in total. Beijing Research Institute of Radiation Medicine is one of the main forces of Beijing, even of China.

Delegates:

Mr. Junxing Dong, Professor, Director of Pharmaceutical Department of Beijing Institute of Radiation Medicine

CV:

PhD, Medicine (Pharmacology), Academy of Military Medical Sciences; M.S., Medicine (Pharmaceutical Chemistry), Second Military Medical University; B.S., Medicine (Pharmacy), Shandong Medical University.
Successful scientist specialized in both basic research and new drugs’ development.
- Basic research: Active pharmaceutical ingredient, pharmacological action, synthesis of the active constituent and structure-function relationship research of Chinese herbal medicine in anti-radiation, anti-virus, anti-Dementia.
- Development of new drugs:
Tel: 8610-68210077-931314; Fax: 8610-68164257;
Cell Phone: 8610-13910840991
Email: dongjx@vip.sina.com

Mr. Shuchen Liu, Director Assistant of R&D Division of Beijing Institute of Radiation Medicine

CV:

M.S., Medicine, Academy of Military Medical Sciences; B.S., Zhengzhou University
More than 10 years experiences in new drugs registration, patent application in China, proficient in all kinds of China’s regulations on application and registration for new drugs.
Familiar with the general situations of R&D capabilities of Beijing Institute of Radiation Medicine.
Tel: 8610-68163454; Fax: 8610-68214653; Mobile: 8610-13501290156
Email: liusc118@yahoo.com.cn

Institute of Materia Medica of Chinese Academy of Medical Sciences & Peking Union Medical College

Brief Introduction:

As one of the primary institutions for drug research in China, the institute was founded in 1958. There are more than 500 employees, of which about 300 are technical staffs including more than 3 academicians of the Chinese Academy of Sciences, 2 academicians of the Chinese Academy of Engineering and 100 professors.

The main task of the institute is searching for new drugs for treatment of commonly occurring diseases that seriously threaten people's health. These include cancer, cardio-cerebral vascular diseases, inflammatory and immunological disease, hepatitis and other viral diseases, disorders of nervous system and retrogression of the old age etc. At the same time, emphasis is put on the application and development of modern medical theory and high technology.

Since the establishment of the Institute, more than 270 prizes have been awarded for its research achievements. More than 100 new drugs have been developed, 3100 scientific papers and 115 monographs have been published, and more than 135 patents, both domestic and abroad, have been applied for.

In addition, a pharmaceutical plant - Beijing Union Pharmaceutical Factory is affiliated with the institute. The main products includes the drugs for treating cancer such as Meisoindigo Tablet with certificate for a national innovative drug, Paclitaxel Injection, Homoharringtonie and etc., the drugs for treating hepatitis such as Bicyclol with more than 15 countries’ patent, the drugs for treating cardio-cerebral vascular drugs such as Puerarin Injection, Felodipine Tablet, and other drugs such as Artificial Moschus and etc.

Delegate:

Mr. Song Wu, Professor, Deputy Chairman of Institute of Materia Medica of Chinese Academy of Medical Sciences in R&D

CV:

Expert in the synthesis of active pharmaceutical natural product
Abundant experiences in the management of new drugs’ research and development
E-mail: wuzuo737@163.com

Beijing Tri-Prime Genetic Engineering Co., Ltd

Brief Introduction:

As one of the first biopharmaceutical companies in China, Beijing Tri-Prime Genetic Engineering Co., Ltd. is a fully integrated biopharmaceutical enterprise. Capitalized on China's first molecular cloning product, interferon a1b, Tri-Prime led the Chinese biotech industry go through countless hurdles. The significant milestones include

Pioneer development of biopharmaceutical products and processes from laboratory to commercial scales,
Navigating the Chinese regulatory and legal systems, and obtaining PMA status
Setting up the first Chinese GMP standard for biopharmaceutical product manufacturing
Educating and communicating with the target market on "cost effectiveness" principle, which has greatly changed the traditional low-expense consumption habit of local people
Successfully steering the ever-changing Chinese distribution system, then competing and winning a fierce price war in a biogeneric market.

Products and Markets
Today, Tri-Prime is a premier biopharmaceutical company with product mix now including pharmaceuticals, vaccines and diagnostic kits. Tri-Prime manages the most important biologic drug - interferon¶¡1b in China and sells the largest number of interferon injections. Hapgen, a patented recombinant interferon¶¡1b for the treatment of viral infections and malignant tumors, such as Hepatitis B and C, herpes zoster, hairy cell leukemia, as well as some other malignant tumors. From the extensive use in a large population in the past eight years, Hapgen reports very low incidence of side effects among all interferon products.

Facilities and R&D
The major components of Tri-Prime production facilities are imported from the US, Germany, France and Japan, thus by themselves meet international standards. In May 1999, the entire facility became the first production line meeting the Chinese State cGMP requirements – We set the new Chinese standards for manufacturing of biologic drugs.

Tri-Prime spends 10% of its annual sales into its R&D, the highest level in Chinese pharmaceutical industry, and thus owns state-of-the-art facilities and a leading R&D organization among its peers. Because of its well-trained and high performing R&D capacity, Tri-Prime maintains strong connections with academic society including many national top research institutes and universities, such as Chinese Academy of Medical Sciences, the Chinese Academy of Military Medical Sciences, the Chinese Centers for Disease Control and the Chinese Academy of Sciences, etc.

Moving Forward&Mac255;
Looking ahead, Tri-Prime is poised to capture a bigger share in the explosively growing Chinese biopharmaceutical market. They will actively pursue mergers and acquisitions strategies to consolidate the Chinese biotech industry. They will also expand their collaborations with overseas partners to acquire technologies and products, as well as for market expansion. It would be a great opportunity for potential international biotech partners to ally and cooperate strategically with Tri-Prime to achieve ever-higher excellent performance.

Delegates:

Mr. Yongqing Cheng, CEO and Board Director of Beijing Tri-Prime Genetic Engineering Co., Ltd

CV:

M.S., Medicine, Peking Union Medical College; MBA, Sino-Europe International Business School, First MBA Class in China
First-hand experiences in bio-medical research, development, manufacture, marketing and administration, in the United States, Germany, France and Japan.
More than 15 years of venture capital investing, operational management experiences.
Previous position: General Manager of Biotech Division of China Kezhao High-tech (Investment) Co., Ltd., 1st VC Fund in China; Board Director and CEO of Kaituo (France) International Shareholding Co., Ltd.
Present position: CEO and Board Director, Beijing Tri-Prime Genetic Engineering Co., Ltd.; Deputy Director of Technical Development Department of Beijing Pharmaceutical Co., Ltd..

Mr. Jianbo Sun, PhD, Senior Vice President of Beijing Tri-Prime Genetic Engineering Co., Ltd

CV:

Research fellow, Johnson & Johnson USA for 4 years
V.P, Beijing Tri-prime Genetic Engineering Co., Ltd since 1992
Add: No. 1 Jinyuan Road, Daxing Industrial Development Zone, Beijing, China; Post Code: 102600
Tel/Fax: (+8610) 69222981
E-mail: jimsun@triprime.com
Website: www.triprime.com

Beijing WBL Peking University Biotech Co., Ltd. (WPU)

Brief Introduction:

As one of the famous enterprises specialized in development of Traditional Chinese Medicine (TCM) and natural products, Beijing WBL Peking University Biotech Co., Ltd. (WPU) was founded in 1994 by the WBL Corporation Limited of Singapore, the renowned Peking University of China and the Beijing Enterprises Holdings Limited of Hong Kong jointly.

Products and Markets
"Xuezhikang", one of primary products of WPU, became an Rx approved by the Ministry of Health of China (Med-drug Permit No: Z10950029) for the prevention and treatment of cardiovascular and cerebrovascular diseases, including hyperlipemia and aterosclerosis. Through the operations in over 26 cities in China, "Xuezhikang" spread over thousands of hospitals and drugstores, which has become the first domestic brand among drugs for lowering blood lipids and occupied relatively large market quota.

The products made of "Specially Made Red Yeast Rice" have been exported to the United States, Japan, Korea, Singapore, Malaysia, Norway, Hong Kong and Taiwan with the brand names of Cholestin, HypoCol, and Lipasco. Total export quotas have exceeded 9 million US dollars.

Facility and R&D
WPU’s manufacture base, locating in Yongfeng Science and Technology Garden in northwest near suburban of Beijing, covers a total of 27000 square meters, with amicable environments and without industrial pollutions. It’s also taken as the base for industrialization of Traditional Chinese Medicine because of its advanced manufacture procedures and strict quality control, which meet the requirements of GMP of the State Food and Drug Administration of China.

As one of members of WPU, Peking University is the technological supporter of WPU, and also offers a R&D team with strong capability. Being aware of the ageing problem of populations, WPU has always engaged in the research and development of natural products for senile diseases, including cardiovascular and cerebrovascular diseases, diabetes, and menopausl syndrome, since its establishment. Besides its leading product "Xuezhikang" capsule, other new products are to be on sale.

Facing the competition among peers, they hope they can learn more about how to establish an efficiency and safe system for new products’ research. And they will attach more importance to the expansion of international market, and are keen to know how to apply for clinical trails in US and meet FDA’s requirements. They welcome the cooperation with overseas.

Delegates:

Mr. Zhenwen Duan, General Manager of Beijing WBL Peking University Biotech Co., Ltd; Senior Engineer of the Peking University

CV:

PhD, Science, Peking University; M.S., Engineering, The Atomic Energy Research Institute of the Department of Nuclear Industry; B.S., Sichuan University
Post Doctorate Studies at Harvard University of the United State
More than ten years experiences in R&D of new drugs, especially in TCM.
Proficiency in the management of a R&D center, development of a new drug, and marketing of a new product.

Mr. Shuren Guo, Chief Technological Officer of Beijing WBL Peking University Biotech Co., Ltd.

CV:

M.D. in pharmacology, Nanjing Medical University
Research field: New Drugs from Natural Herb and Microbial Medicine
Tel /Fax: 010-82629271
E-mail: guosrpku@263.net
Website: www.wpu.com.cn

Starvax Inc.

Brief Introduction:

Starvax Inc. is an emerging biopharmaceutical company providing pre-clinical contract research services for in vivo studies. Leveraging the cost-savings and other advantages of drug development in China, the company’s objective is to provide high quality services with much lower cost for global biotech and pharmaceutical companies.

Founded by a group a US-educated entrepreneur in 2003, the company has grown to 24 full time employees, most of which have advanced degrees in biomedical sciences. Starvax provides services in animal modeling (including non-human primates), in vivo drug efficacy test, PK/PD analysis, and toxicity test. With extended local research network and proven collaboration track record, Starvax is the preferred partner for low cost drug development

Delegate:

Mr. Yiyou Chen, PhD, President and Chief Scientist Officer of Starvax Inc.

CV:

Postdoctoral fellow at University of Utah Department of Pathology, conducting research on the functions of Pactolus, a gene he discovered in 1997.
Successful scientist. Dr. Chen was a senior scientist at Genencor International Inc., a large US biotech company with over 380 million dollar revenue each year and has served a co-project leader for the immunotherapeutic program covering HBV and HPV. The program was later sold to Innogenics for 90 million dollars.
An enterpriser. Dr. Chen is the co-founder of Starvax Inc., and is responsible for the overall scientific direction of the company
E-mail: yychen@starvax.com

Vector Gene Technology Co., Ltd.

Brief Introduction:

Vector Gene Technology Company Limited £®VGTC£©, established in Oct. 2000, is an expert in gene vector technologies, primarily engaged in the research and development of gene transfer technologies and gene therapeutics. The significant honors includes:

R&D Base of Viral Gene Vector under the National Hi-tech Research and Development Program of China 863 Project
Awarded "New High Technology Enterprise Certificate" by the Beijing Science and Technology Commission
Authorized by the Ministry of Personnel of the P.R.CHINA to set up a workstation for post-doctoral research
The industrialization project of gene vector technology platform has been recognized by the State Development Planning Commission as "National Exemplary Project of Hi-Tech industrialization"
Awarded certification of significant high-tech achievement transformation by the Beijing Municipal Government

An Outsourcing Services Provider
VGTC is a leader in recombinant adeno-associated virus (rAAV) large-scale manufacturing. Its novel AAV package and purification systems make the producing of AAV to be one of the most cost-effective AAV producing systems

With the advent of viral and plasmid-DNA mediated vaccine and gene therapy, VGTC used its decade of experiences in virology and cell culture to offer a GMP contract production service, adeno-associated viral vectors and DNA vectors. The manufacturing service, ranging from research grade scale to cGMP-compliant clinical grade scale, makes it easy for our clients to meet their different demands.

The company has provided more than hundreds times of non-GMP manufacturing services for theit customers in Mainland China, Hong Kong, Australia and Canada. Meanwhile, dozens batches of AAV, AdV or DNA GMP manufacturing in compliance with the current BioManufacturing Guideline of SFDA (FDA in China) were performed. Till now, three of these products have received permit from SFDA and used in Phase I human clinical trials in China.

Facility
In July of 2002, increased business allowed VGTC to move into its own buildings including 4,300 sq. ft. GMP facility with class 10,000 cleanrooms, 8,600 sq. ft. GLP laboratory and 1,100 sq. ft. SPF animal laboratory.

VGTC's services, capabilities, and talented workforce have significantly increased over the last several years. The company's client base has grown to a global scale. The company is collaborating with a number of groups worldwide to develop new Gene Therapy and Vector Vaccine technologies. Other synergistic partnerships are being aggressively pursued.

Delegate:

Ms. Xiaobin Wu, Professor, Chief Scientific Officer of Vector Gene Technology Co., Ltd. (VGTC)

CV:

PhD, Biochemistry, The Fourth Military Medical University, Xi'an; M.S., Biochemistry, The First Military Medical University, Guangzhou; B.S., The First Military Medical University, Guangzhou.
Post doctoral fellow at National Key Laboratory of Molecular Virology and Genetic Engineering, Beijing
Tel: 8610-67871177-111; Fax: 8610-67877776
E-mail: wuxb0168@vip.sina.com.cn; wu_xb@vgtc.com.cn
Website: www.vgtconline.com

Mediking Pharmaceutical Co. Ltd

Brief Introduction:

Beijing Mediking Pharmaceutical Co. Ltd. (Beijing Mediking), a famous pharmaceutical R&D company located in Beijing, China, and is employing more than 50 researchers and experts in conducting sophisticated R&D of chemical intermediates, custom synthesis and APIs.

In the past five years, Beijing Mediking have cooperated with top two pharmaceutical companies (Yangtz river pharmacy group and Harbin pharmacy group) and five other famous quoted companies in China on more than 20 projects.

In order to ensure the feasibility of the projects, we also cooperate with some famous universities and research institutes, such as Beijing University, Shenyang Pharmaceutical University, Lanzhou University and Chinese Academy of Sciences, etc. on R&D projects such as chiral drugs, high pressure hydrogenation reaction.

Custom Synthesis & APIs manufacturer
As a custom synthesis and APIs manufacturer with 3 years experience serving the pharmaceutical industry, Beijing Mediking concentrates on multi-step synthesis of complex downstream pharmaceutical intermediates. Solid annual fiscal growth every year since our beginning correlates with the level of satisfied customers in our products’ consistent quality and delivery. For projects from Phase I to III up to launched, has the existing capacity, technological know-how and equipment to handle the synthesis at each step of the process in-house.

In Feb 2004, Tianjin Mediking Pharmaceutical Co. Ltd (Tianjin Mediking) was founded, now it has about 80 employees. The new cGMP pilot and commercial scale plant, total area is 45,711m2, has been invested $3 millions, with capacity of more than 40T of intermediates and APIs per annum. Tianjin Mediking will transfer 5-10 products per year from lab scales to pilot or commercial scales.

Now we are targeting to cooperate with US companies to pass the FDA inspection in two years.

APIs Marketing services
From 2003, Beijing Mediking built a professional sales team for pharmaceutical intermediates and APIs, serving clients both locally and internationally. Till 2005, our pharmaceutical intermediates and APIs have been exported to Europe , Japan, Israel, India, Korea and Hongkong etc. Our export sales will reach $ 600 thousand in this year and it is expected to reach $10 million in 2007.

Facilities
Beijing Mediking Pharmaceutical Co.Ltd.,
R & D facilities: 100% owned subsidiary, SFDA certified, 40,000sft.
R&D Process support labs 3,000sft
Supports the lab-scale inventory
Production 400sft
Glass-lined reactors: 50mL to 40L.
Bench fume hoods : 8ft_60
Walk-in fume hoods: 10ft_10
Development of core technology from which Mediking’s expertise is built.

Tianjin Mediking Pharmaceutical Co.Ltd.,
100% owned subsidiary, is preparing for FDA cGMP certified, 12 acres.
QC center : HPLC,GC and IR in-house.
Kilo-lab 2,000sft: Low temperature capacity down to -20°Ê
Walk-in fume hoods: 10ft_5
This multi-purpose Kilo-Lab carries out kilo production and refines R&D’s procedures to develop a commercially viable process for further scale-up. Basic chemistry and chemical engineering data are integrated to carry out scale-up processes.
cGMP standard plant: 10,000sft
Low and High temperature Enamelware reactors, stainless steel reactors down to -20°Ê and up to 300°Ê: 50L to 5000L size, total 44,000L.
Autoclaves: 20L to 500L up to 100atm.
The Pilot Plant validates processes developed in R&D and scaled-up in Kilo-Lab, handling production ranging from several kg’s to 300kg’s.
Working temperature -20°Ê to 300°Ê.

Delegate:

Ms. Feng Gao, General Manager, Mediking Pharmaceutical Co. Ltd.

M.S., photochemistry, Shenyang Pharmaceutical University.
Familiar with almost every key steps of pharmaceutical industry including technology, management and policies.
During 1996-1998, worked for Beijing Drug Evaluation Institute.
During 1998-2000, regulatory affairs manager and clinical trials supervisor, Beijing Jinjiang Sini Pharmaceutical Co. Ltd.
In 2000, established Beijing Mediking Pharmaceutical Co. Ltd., a joint venture company, and took as general manager and vice president
In 2004, founded Tanjing Mediking Pharmaceutical Co. Ltd.
Address: Beijing Mediking Pharmaceutical Co. Ltd., Hongxianghong Incubator, Beiqijia City ,Changping district, Beijing, China PC: 102209
Tel: £®8610£©-81769601
Fax: £®8610£©-81769652
E-mail: gaof@herbkingpharm.com

Zen,Chung Hei Hayley, CEO, Herb King Life Sciences, Inc., a investor of Mediking Pharmaceutical Co. Ltd.

EMBA, Peking University; B.Com, majoring in accounting, University of Auckland, New Zealand; B.S, majoring in computer science, University of Auckland, New Zealand.
Member of Hong Kong Society of Accountant (Since 2003)
Member of Institute of Accountants of New Zealand (Since 1999)
From Oct 99 till now, Herb King Life Sciences, Inc., CEO, looking after the overall day to day operation of the Group
From Apr 99 to Oct 99, Senior Accountant, Emerging Markets Partnership, USA(EMP)
From Jan 96 to Apr 99, Senior Auditor, Deloitte Touche Tohmatsu

Top^ Close window